	US 11,957,737 B2
	Methods of treating microbial infection and inflammation
John Repine, Englewood, CO (US); and Amani Alhalwani, Jeddah (SA)
Assigned to COLORADO SEMINARY, OWNER AND OPERATOR OF UNIVERSITY OF DENVER, Denver, CO (US); and THE REGENTS OF THE UNIVERSITY OF COLORADO, Denver, CO (US)
Filed by Colorado Seminary, Owner and Operator of University of Denver, Denver, CO (US); and The Regents of the University of Colorado, Denver, CO (US)
Filed on Jun. 30, 2022, as Appl. No. 17/855,278.
Application 17/855,278 is a continuation of application No. 16/761,215, granted, now 11,376,311, previously published as PCT/US2018/058626, filed on Nov. 1, 2018.
Claims priority of provisional application 62/580,563, filed on Nov. 2, 2017.
Prior Publication US 2022/0362349 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5513 (2006.01); A61K 9/00 (2006.01); A61K 31/4164 (2006.01); A61K 31/66 (2006.01); A61K 35/74 (2015.01); A61K 38/40 (2006.01); A61P 31/04 (2006.01)

CPC A61K 38/40 (2013.01) [A61K 9/0048 (2013.01); A61K 31/4164 (2013.01); A61P 31/04 (2018.01)]

16 Claims

1. A composition comprising:

ergothioneine (ERGO) or a pharmaceutically acceptable salt thereof,

lactoferrin,

at least one viscosity enhancing agent, and

a pharmaceutically acceptable carrier,

wherein the ERGO enhances an anti-microbial activity of the lactoferrin.